Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin Rollover Study
NCT01353664Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in lymphoma, sponsored by Celgene Corporation. Primary endpoint: Treatment Emergent Adverse Events. Started May 2011; status: completed.
02
Drugs
romidepsin
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT01353664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01353664.